Okay, at a regional level, thank you, Monika. At a regional level, the Americas continue to perform exceptionally strongly. Sales in the quarter were 89 million SEK, which is up 32%. And this has really been driven by demand for large connected platforms, as our platform has the flexibility to connect smaller and large laboratories, and demand for that as laboratories consolidate is really helping drive sales in that region. In this quarter, the most notable win was a significant tender in Canada, which has led to a large installation in that region. If we look at EMEA, sales were 86 million SEK, down from last year, but after the inventory correction in quarter one, we have now seen underlying growth represented through two consecutive quarters of growing sales. Interesting here, looking to the future. Bone Marrow Aspirate has started. As I mentioned earlier, evaluations are generating positive feedback. And that is leading to early adoption, which is leading to growth. And we expect sales in the quarter to represent 1% to 2% of the growth. Reagent growth continues to strengthen across EMEA. And this is positive for us because this is recurring revenue, and this is an important part of the combined value offering or value proposition of CellaVision. Both reagents and the microscopy combined give us a good platform and make us a more attractive proposition for laboratory customers. If we then look at APAC, we see really pleasing sales here with 90% growth in the quarter, all outside of China. This has been driven across the portfolios of both instruments and reagents, which are growing stronger. It is across the region, both in South Asia and East Asia. I do want to call out the Japan performance here, which was fantastic and really has been driven by a conversion to CellaVision reagents in the largest national laboratory chain there.
So a very pleasing result when you look at it across the three regions. If we look briefly at sales by product group, instruments represented 105 million SEK in the quarter, up 14%. As I've said, driven by the larger platforms in the Americas, reagents were up 12% at 45 million. SEK. And again, this is pleasing for us. This is a region that we have focused on. And sales have positively developed there, in Asia, as I've mentioned, and in EMEA.
And then finally, a word on software and spare parts sales. There are 49 million SEK. SEK were up 15%, again driven by increased software sales, again driven by the Americas. To summarize the key takeaways, the quarter resulted in net sales that are up 13.6%, as I've said, driven by 32% growth in the Americas. EMEA is 10% down on last year, representing a tough comparison. But quarter on quarter, we are seeing underlying growth on both the reagents and on the BMA Application platform and in APAC, really strong performance there driven by Japan. All of this is outside of China, and it is across both the reagents and the instrument platform. I just want to call out before we close today that the Power of Focus strategy was put in place to cover the five years up to 2025, and that strategy has delivered across multiple areas for us. And we have made commercial and regulatory progress with the Bone Marrow Aspirate and reached a meaningful milestone. That is our first significant launch in that period. Following quickly on that will be the development of the Fourier Ptychographic Microscopy technology. So our innovation pipeline is extremely strong. I would like to highlight to you that we plan to take you through the revised strategy. So we have a new strategy period, a new strategy focus, and we plan to launch that. To provide more insight into that, we will host our Capital Markets Day on February 17th next year in Stockholm. So a heads up for now to hold that date. Those are the final remarks today. So with that, I'll pause and hand over for any questions.